Clinical Trials Directory

Trials / Completed

CompletedNCT04683562

Netrin-1 and Placenta Accreta

The Implication of Placental Netrin-1 Receptor DCC in the Pathophysiology of Placenta Accreta

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
34 (actual)
Sponsor
Assiut University · Academic / Other
Sex
Female
Age
20 Years – 40 Years
Healthy volunteers
Not accepted

Summary

Netrin-1 is a secreted protein, which was first identified as a neuronal guidance factor. It is expressed in a multitude of tissues as pancreas, lung, breast, and placenta. Netrin-1 is a multifunctional protein, involved in cell polarity, adhesion, angiogenesis, apoptosis, migration, morphogenesis, and differentiation of various cell types. Most of netrin-1 activity occur through signaling pathways induced by its two main receptors, DCC (deleted in colorectal cancer) and UNC5H (uncoordinated-5 homolog). Its receptors have been linked to the processes of apoptosis and angiogenesis. In absence of netrin-1, DCC and UNC5H receptors lead to apoptosis. In contrary, in presence of netrin-1, receptors transduce molecular cascades leading to proliferation, differentiation and migration of the cells. Netrin-1 has been involved in the pathogenesis of multiple diseases, as diabetes, cardiovascular diseases, and cancer. Serum Netrin-1 levels were high in preeclamptic patients.

Conditions

Interventions

TypeNameDescription
OTHERPregnant women at 28-32 weeksPregnant women at gestational age 28-32 weeks
OTHERat deliverywomen delivered at term

Timeline

Start date
2021-12-01
Primary completion
2022-06-01
Completion
2022-06-01
First posted
2020-12-24
Last updated
2022-08-22

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT04683562. Inclusion in this directory is not an endorsement.